Silence Therapeutics (SLN) Total Liabilities (2018 - 2026)

Silence Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $65.7 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 9.42% year-over-year to $65.7 million; the TTM figure through Mar 2026 stood at $65.7 million (down 9.42% YoY), while the FY2025 annual figure was $69.1 million, up 0.77% from the prior year.
• Total Liabilities came in at $65.7 million for Q1 2026 at Silence Therapeutics, down from $69.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $111.1 million in Q1 2022 to a low of $65.7 million in Q1 2026.
• A 5-year average of $89.4 million and a median of $95.3 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 569.81% in 2022 and declined 27.99% in 2024, its largest moves.
• Silence Therapeutics' Total Liabilities stood at $100.2 million in 2022, then decreased by 4.91% to $95.3 million in 2023, then slipped by 27.99% to $68.6 million in 2024, then grew by 0.77% to $69.1 million in 2025, then slipped by 4.94% to $65.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $65.7 million, $69.1 million, and $72.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison